A dimer peptide ligand of vascular endothelial growth factor slows the progression of human gastric tumors in mouse xenografts
Open Access
- 3 August 2026
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0344142
Abstract
Gastric cancer is among the most common cancers and represents a major public health problem worldwide. New therapeutic strategies and drugs are needed. Anti-angiogenic agents targeting the Vascular Endothelial Growth Factor (VEGF) are used in combination therapy in the clinic, although their efficacy remains modest. We believe that these large anti-VEGF antibodies could be advantageously replaced by smaller peptides with better tissue penetration. In this study, we evaluate the efficacy of a previously described dimer peptide ligand of VEGF, D6 , in inhibiting the proliferation of gastric cancer cells and the growth of the corresponding murine xenograft. The activity of the D6 peptide in these assays was comparable to that of bevacizumab, the positive control antibody, although the peptide required repeated injections at higher molar concentrations. These promising results justify the continued optimization of the peptide dimer, currently under investigation in our laboratory.Keywords
This publication has 23 references indexed in Scilit:
- Gastric cancerThe Lancet, 2025
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccinesSignal Transduction and Targeted Therapy, 2025
- Dimer Peptide Ligands of Vascular Endothelial Growth Factor: Optimizing Linker Length for High Affinity and Antiangiogenic ActivityJournal of Medicinal Chemistry, 2023
- Therapeutic peptides: current applications and future directionsSignal Transduction and Targeted Therapy, 2022
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlookCancer Treatment Reviews, 2020
- Vascular Endothelial Growth Factor Peptide Ligands Explored by Competition Assay and Isothermal Titration CalorimetryBiochemistry, 2015
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialThe Lancet Oncology, 2014
- Vascular Endothelial Growth Factor A Inhibition in Gastric CancerGastric Cancer, 2014
- Neutral red uptake assay for the estimation of cell viability/cytotoxicityNature Protocols, 2008
- Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding SiteBiochemistry, 1998